AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
AbbVie Inc. (ABBV) identifies John Carethers as a director in a Form 3 ownership filing.
AbbVie Inc. (ABBV) expanded its Board of Directors from 12 to 13 directors on October 14, 2026, appointing Dr. John M. Carethers as a Class II director. Dr. Carethers serves as Vice Chancellor for Health Sciences at the University of California San Diego and was previously a director of Avantor, Inc.
Dr. Carethers joins the Public Policy and Sustainability Committee. The Board determined that he meets the independent-director standards in the New York Stock Exchange Listed Company Manual and AbbVie’s governance guidelines. He is entitled to compensation as an independent director under terms disclosed in AbbVie’s quarterly report for the period ended March 31, 2025.
AbbVie Inc. revised its 2026 adjusted diluted EPS guidance to $13.76–$13.96, including an estimated $216 million pre-tax acquired IPR&D and milestones expense for the third quarter. The full-year guidance table lists $1,251 million in acquired IPR&D and milestones expense. Third-quarter adjusted diluted EPS guidance is $3.73–$3.77 per share.
AbbVie expects the $216 million expense to have an unfavorable $0.11 impact on both GAAP diluted EPS and adjusted non-GAAP diluted EPS. Previously announced guidance was $13.87–$14.07 for full-year 2026 and $3.84–$3.88 for the third quarter, excluding the third-quarter expense.
Results for the quarter ended September 30, 2026 have not been finalized and remain subject to financial statement closing procedures; AbbVie cautioned that final results may differ from these estimates. 2026 adjusted diluted EPS guidance excludes acquired IPR&D and milestones expense that may be incurred beyond the third quarter, which AbbVie says cannot be reliably forecast.
AbbVie Inc. director Susan E. Quaggin acquired 59 Stock Equivalent Units on September 30, 2026, at a reported price of $261.59 per share. Her reported balance after the transaction was 918 Stock Equivalent Units, including units acquired through a dividend reinvestment feature. The reported units are held directly.
AbbVie Inc. director Edward J. Rapp acquired 129 Stock Equivalent Units on September 30, 2026, as director fees were credited to a stock equivalent unit account under his grantor trust. His reported balance was 29,568 Stock Equivalent Units, including units acquired through dividend reinvestment. The units earn the same return as if the fees were invested in AbbVie stock; distributions generally begin at the later of age 65 or retirement from the board and are spread over a period equal to his years of board service.
AbbVie Inc. (ABBV) announced completion of its acquisition of Apogee Therapeutics, Inc. for $135.11 per share in cash, implying a total equity value of approximately $10.9 billion, adding late-stage and early-stage immunology assets focused on atopic dermatitis, asthma and COPD. Apogee is now part of AbbVie.
Apogee’s lead drug candidate zumilokibart (APG777), a half‑life extended IL‑13 monoclonal antibody for atopic dermatitis, showed in a Phase 2 trial that about two‑thirds of patients achieved significant skin clearance at 16 weeks, with sustained control enabling quarterly or twice‑yearly dosing, and a favorable safety profile. Combination candidate APG273, which includes an antibody blocking TSLP, is being developed for asthma with data supporting long‑acting dosing.
AbbVie expects the acquisition to reduce adjusted diluted EPS by $0.14 in 2026 and about $0.46 in 2027, with accretion beginning in 2032, but is reaffirming its 2026 full‑year adjusted diluted EPS guidance range of $13.87–$14.07 and third‑quarter 2026 adjusted diluted EPS guidance of $3.84–$3.88. The 2026 EPS outlook includes an unfavorable $0.58 per share impact from acquired IPR&D and milestones recorded through the second quarter.
AbbVie Inc. (ABBV) reported insider equity transactions by EVP and Chief Business/Strategy Officer Nicholas Donoghoe on August 14, 2026. Donoghoe exercised employee stock options for 32,710 shares of common stock at an exercise price of $79.02 per share under AbbVie’s 2013 incentive stock program, then sold 32,710 shares of common stock in a separate transaction. The options exercised were from a grant that vested in annual increments between 2020 and 2022 and now show 0 options remaining from this specific grant.
AbbVie Inc. (ABBV) completed an underwritten public offering of multiple series of unsecured, unsubordinated senior notes to help finance its previously announced acquisition of Apogee Therapeutics, Inc. The offering includes $500,000,000 senior floating rate notes due 2028 and eight series of fixed-rate notes.
The fixed-rate series comprise $1,000,000,000 of 4.500% notes due 2028, $1,250,000,000 of 4.650% notes due 2030, $1,500,000,000 of 4.875% notes due 2031, $1,250,000,000 of 5.050% notes due 2033, $1,500,000,000 of 5.300% notes due 2036, $1,000,000,000 of 5.450% notes due 2038, $1,500,000,000 of 6.000% notes due 2056 and $500,000,000 of 6.100% notes due 2066.
The floating rate notes and 4.500% 2028 notes mature on August 18, 2028; the 2030 notes mature on March 15, 2030; all other fixed-rate series mature on September 15 of their stated year. AbbVie expects to use the net proceeds primarily to pay a portion of the cash consideration to Apogee shareholders and related fees, with any remainder for general corporate purposes. If the Apogee acquisition is not pursued or the definitive agreement is terminated, AbbVie must redeem all notes maturing between 2028 and 2038 at 101% of principal plus accrued interest under a special mandatory redemption.
AbbVie Inc. is issuing a total of $10.0 billion of unsecured senior notes in nine series, including $500 million floating rate notes due 2028 and eight fixed-rate tranches maturing between 2028 and 2066 with coupons ranging from 4.500% to 6.100%. The notes rank equally with AbbVie’s existing unsecured senior debt and are structurally subordinated to obligations of its subsidiaries.
AbbVie expects net proceeds of approximately $9.93 billion, to be used to fund a portion of the $10.9 billion cash acquisition of Apogee Therapeutics, related fees, and for general corporate purposes, including potential debt repayment. If the Apogee acquisition is not pursued or the acquisition agreement is terminated, AbbVie must redeem the floating-rate and shorter- to medium-term fixed-rate notes at 101% of principal plus accrued interest, while the 2056 and 2066 notes are excluded from this special mandatory redemption.
As of June 30 2026, AbbVie had $68.4 billion of unsecured senior notes outstanding and, on a pro forma basis including this offering, total indebtedness would be about $80.4 billion. The company also has a $10.0 billion 364-day delayed draw term loan, $8.0 billion of unused revolving credit capacity, and a $2.0 billion term loan due 2027.